Ieq Capital LLC Acquires New Stake in BioMarin Pharmaceutical Inc. $BMRN

Key Points

• Ieq Capital LLC acquired 197,988 BioMarin shares worth approximately $11.3 million, representing about 0.10% of the company. Institutional investors collectively own 98.71% of BMRN.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $88.83. Recent targets range from $59 to $114.
• BioMarin beat quarterly earnings expectations, reporting $1.20 in EPS versus $0.95 expected and revenue of $989.71 million, up 20% year over year. Shares opened at $66.70, while the company issued fiscal 2026 EPS guidance of $4.90–$5.10.

Ieq Capital LLC acquired a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 197,988 shares of the biotechnology company's stock, valued at approximately $11,329,000. Ieq Capital LLC owned approximately 0.10% of BioMarin Pharmaceutical as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BMRN. CIBC Private Wealth Group LLC grew its holdings in shares of BioMarin Pharmaceutical by 38.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company's stock worth $39,000 after buying an additional 179 shares in the last quarter. Northwestern Mutual Investment Management Company LLC lifted its stake in shares of BioMarin Pharmaceutical by 0.4% in the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 42,982 shares of the biotechnology company's stock worth $2,554,000 after buying an additional 183 shares in the last quarter. Caerus Investment Advisors LLC lifted its stake in shares of BioMarin Pharmaceutical by 2.8% in the fourth quarter. Caerus Investment Advisors LLC now owns 10,236 shares of the biotechnology company's stock worth $608,000 after buying an additional 278 shares in the last quarter. Chicago Partners Investment Group LLC boosted its position in BioMarin Pharmaceutical by 2.4% during the first quarter. Chicago Partners Investment Group LLC now owns 12,183 shares of the biotechnology company's stock worth $660,000 after acquiring an additional 290 shares during the last quarter. Finally, Parallel Advisors LLC boosted its position in BioMarin Pharmaceutical by 62.2% during the third quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company's stock worth $42,000 after acquiring an additional 295 shares during the last quarter. Hedge funds and other institutional investors own 98.71% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have commented on BMRN. BMO Capital Markets started coverage on shares of BioMarin Pharmaceutical in a report on Wednesday. They issued an "outperform" rating and a $98.00 price objective for the company. Canaccord Genuity Group boosted their target price on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock a "buy" rating in a report on Monday, August 10th. The Goldman Sachs Group started coverage on BioMarin Pharmaceutical in a report on Monday, May 11th. They set a "neutral" rating and a $69.00 target price on the stock. Royal Bank Of Canada dropped their price target on BioMarin Pharmaceutical from $66.00 to $62.00 and set a "sector perform" rating for the company in a research report on Tuesday, July 7th. Finally, HC Wainwright cut their price target on BioMarin Pharmaceutical from $60.00 to $59.00 and set a "neutral" rating for the company in a report on Tuesday, August 18th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $88.83.

BioMarin Pharmaceutical Trading Down 1.4%

Shares of BioMarin Pharmaceutical stock opened at $66.70 on Friday. The firm has a market capitalization of $12.91 billion, a price-to-earnings ratio of 180.27, a PEG ratio of 0.48 and a beta of 0.24. BioMarin Pharmaceutical Inc. has a fifty-two week low of $49.26 and a fifty-two week high of $70.98. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. The stock has a 50 day moving average of $60.67 and a 200 day moving average of $57.88.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating the consensus estimate of $0.95 by $0.25. The business had revenue of $989.71 million for the quarter, compared to analyst estimates of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The company's quarterly revenue was up 20.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. As a group, research analysts predict that BioMarin Pharmaceutical Inc. will post 4.1 earnings per share for the current year.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company's commercial portfolio includes several approved therapies targeting inherited disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source